List view / Grid view
Enzymes are macromolecular biological catalysts. Enzymes accelerate, or catalyse, chemical reactions.
New findings from collaborative research in the United States have identified a promising new treatment avenue for type 2 diabetes patients centring on the activity of the amino acid, GABA.
Researchers have shown in fruit flies that lipid droplets could prevent the kidney damage that leads to chronic kidney disease.
The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) can block cell death, new research has shown, making it a cancer drug target.
Scientists have developed a drug called STM2457 which inhibits a key enzyme involved in acute myeloid leukaemia.
Scientists have discovered that manipulating residues enables precision during the antibiotic biosynthesis assembly line.
Researchers have shown that miR-29 can control brain maturation in mammals, presenting a target for autism, epilepsy and other conditions.
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
Researchers have shown that the PLpro coronavirus enzyme presents a possible target in the fight against COVID-19.
Using X-ray crystallography and simulations, researchers have shown that APT2 is a hybrid between a lipid carrier protein and a hydrolase.
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.
A new coarse-grained model of the complete SARS-CoV-2 virion has revealed potential new ways to combat the coronavirus.
Research has shown that MAPK4 activates two molecules in cellular signalling pathways involved in prostate cancer growth.
Vito Quaranta, professor of biochemistry and pharmacology, discusses how cancerous cells adopting novel mechanisms of energy production could be sensitised to existing therapies with a focus on melanoma.
A study has shown that inhibiting the enzyme PRMT5 can suppress the growth of glioblastoma cells in pre-clinical studies.
Researchers have discovered that all childhood neuroblastomas come from sympathoblasts, making them a drug target to treat the condition.
